Sutro Biopharma Inc
Sutro Biopharma Inc (STRO) Covered Calls
Sutro Biopharma Inc trades in the Biotechnology industry with an IV Rank of 84.52%, high versus the past year. STRO's highest covered call setup is the $10.00 strike expiring Feb 19, 2027, sorted by theoretical annualized return. It's 16.28% out of the money with 91 days to expiration, a 17.44% return until expiration, and a 69.96% theoretical annualized return. Across the setups shown, annualized returns run from 39.64% to 69.96% at strikes between $10.00 and $10.00, with 91 to 182 days to expiration, as of Nov 20, 2026.
Read more
Running STRO covered calls helps you generate income from Sutro Biopharma Inc shares you already own, turning a long stock position into a yield producing asset. A covered call means holding the underlying stock and selling a call option against it, collecting premium in exchange for capping upside at the strike. Use our scanner to find the best STRO covered calls in real time and filter for the strikes, expiries, and premiums that fit your strategy.
A covered call pairs limited risk with a clear income profile. If STRO stays below the strike at expiration, you keep the premium and the shares. If it rises above, you deliver the stock at the strike and still pocket the premium. Selling STRO covered calls works best when implied volatility is elevated, since richer premiums improve the risk reward. Key inputs include strike selection relative to delta, days to expiration, annualized return, and probability of assignment, all of which determine whether a given STRO covered call is worth writing.
Sutro Biopharma, Inc. operates as clinical stage drug discovery, development, and manufacturing company. It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis and site-specific conjugation platform, XpressCF+.The company's product candidates include STRO-001, an antibody-drug conjugate (ADC) directed against the cancer target CD74 for patients with multiple myeloma and non-Hodgkin lymphoma that is in Phase 1 clinical trials; and STRO-002, an ADC directed against folate receptor-alpha for patients with ovarian and endometrial cancers, which is in Phase 1 clinical trials.
| 2027-02-19 | 91 | 10.00 | 16.28 | 0.10 | 4.90 | 150.00 | 17.44 | 69.96 | -1.16 | +0.61 | 0 | 4.80 |
| 2027-05-21 | 182 | 10.00 | 16.28 | 0.30 | 4.90 | 170.00 | 19.77 | 39.64 | -3.49 | +0.62 | 130 | 4.60 |
As of Nov 20, 2026
Prices move. This one stays.Lock in 5 years at a special price and save $1,503. Ending soon.See the Black Friday deal →Stock Statistics
- IndustryBiotechnology
- SectorHealthcare
- IV Rank84.52% High
- Market cap (M$)143
- 52 weeks high-80.39%
- 52 weeks low20.28%
- Analyst recommendationStrong Buy
1.29 - Target price$44.69
419.65% above the current stock price - Dividend—
- Payout ratio—
- Earnings date2026-11-12
- P/E—
- Future P/E—
- EPS (ttm)-12.61
- EPS growth next 5 years30.85%
As of Nov 20, 2026